Q3 2025 · 13F-HR
Propel Bio Management, LLCholdings as filed
Filed 2025-11-12 · accession 0000898432-25-000886
$99.9M
Reported value
16
Positions
2025-09-30
Period end
The Brief · Propel Bio Management, LLC · Q3 2025
AI · grounded in 13F
Propel Bio Management, LLC established a new position in PAGP valued at $23.2M. The fund also initiated new stakes in ACHV for $11.9M and AKRO for $10.9M. Additional new positions include MIST, APLT, and PHAT. The fund ended the period with 16 positions and total AUM of $99.9M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 72651A207 | PAGP | PLAINS GP HOLDINGS LP-CL | $23.2M | 23.2% | 1,272,360 | Common | SHARED |
| 004468500 | ACHV | ACHIEVE LIFE SCIENCES INC | $11.9M | 11.9% | 3,786,425 | Common | SOLE |
| 00973Y108 | AKRO | AKERO THERAPEUTICS INC | $10.9M | 10.9% | 228,884 | Common | SHARED |
| 59935V107 | MIST | MILESTONE PHARMACEUTICALS | $10.2M | 10.3% | 5,124,890 | Common | SHARED |
| 03828A101 | APLT | APPLIED THERAPEUTICS INC | $6.8M | 6.83% | 11,285,420 | Common | SOLE |
| 71722W107 | PHAT | PHATHOM PHARMACEUTICALS I | $6.5M | 6.51% | 552,927 | Common | SHARED |
| 00289Y206 | ABEO | ABEONA THERAPEUTICS INC | $5.1M | 5.15% | 974,022 | Common | SHARED |
| 24661P807 | DCTH | DELCATH SYSTEMS INC | $4.7M | 4.72% | 438,509 | Common | SHARED |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC | $4.0M | 4.01% | 155,000 | Common | SHARED |
| 89854M101 | TCRX | TSCAN THERAPEUTICS INC | $3.5M | 3.52% | 1,932,304 | Common | SOLE |
| 20451W101 | CMPS | COMPASS PATHWAYS PLC | $2.9M | 2.93% | 510,000 | Common | SHARED |
| 640268306 | NKTR | NEKTAR THERAPEUTICS | $2.8M | 2.79% | 49,000 | Common | SHARED |
| 471871202 | JSPR | JASPER THERAPEUTICS INC | $2.4M | 2.45% | 1,028,806 | Common | SHARED |
| 488445206 | ZVRA | ZEVRA THERAPEUTICS INC | $2.2M | 2.21% | 231,874 | Common | SHARED |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $1.9M | 1.94% | 90,000 | Common | SHARED |
| 04746L203 | LONA | ATHIRA PHARMA INC | $618,015 | 0.62% | 149,279 | Common | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.